RxDoctor Payments Data

Mark Perini, MD

Internal Medicine · Greensboro, NCNPI 1538185574

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 191 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$560
  • Abbott$233
  • Sanofi Pasteur Inc.$206
  • AstraZeneca$178
  • Pfizer$171
  • Radius Health, Inc.$170
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$3,05594%
  • Education$2066%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,261 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$180,284
Medicare patients
253
Services billed
4,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$258,139
Repatha SureclickEvolocumab272$252,558
JardianceEmpagliflozin92$112,526
MounjaroTirzepatide73$85,346
MyrbetriqMirabegron131$76,638
Praluent PenAlirocumab48$54,688
OzempicSemaglutide48$48,032
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$38,259
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$31,776
XareltoRivaroxaban25$30,905
TradjentaLinagliptin41$30,318
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$29,436
Breo ElliptaFluticasone/Vilanterol57$27,276
FarxigaDapagliflozin Propanediol40$26,114
Lagevrio (Eua)Molnupiravir44$21,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$171$282,892326 claims
Boehringer IngelheimJardiance, Tradjenta$59$142,844133 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$167$106,230200 claims
Lilly USA, LLCMounjaro, Trulicity$155$106,15189 claims
Astellas Pharma US IncMyrbetriq$99$76,638131 claims
Novo NordiskOzempic$79$48,03248 claims
MerckLagevrio (Eua), Januvia, Belsomra$12$46,81379 claims
AstraZenecaFarxiga, Symbicort$178$35,96361 claims
AbbVieLinzess, Ubrelvy, Synthroid$560$33,851105 claims
Johnson & JohnsonXarelto$36$30,90525 claims
NovartisEntresto$107$20,02623 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$71$9,14412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →